HM Venture Partners

HM Venture Partners is a healthcare venture capital firm committed to accelerating the development of early and growth-stage healthcare companies by leveraging its team's expertise and extensive global ecosystem. The firm invests worldwide from its offices in San Francisco, California; Rochester, Minnesota; and Beijing, China. HM Venture Partners focuses on sectors such as biotech, medtech, healthcare IT, healthcare services, medical devices, biopharmaceuticals, diagnostics, healthcare AI, clinical research organizations, in vitro diagnostics, healthcare platforms, immunotherapy, oncology, cardiology, and respiratory diseases. The firm's investment strategy encompasses early and growth stages, with a geographical focus on the United States, China, and global markets. HM Venture Partners has a track record of successful investments, including OncoImmune Inc., a biopharmaceutical company acquired by Merck & Co., and OncoC4 Inc., a spin-off from OncoImmune. The firm's portfolio also includes Airiver Medical Inc., which develops drug-coated balloons for treating airway stenosis and asthma. HM Venture Partners is dedicated to partnering with category-defining healthcare businesses, contributing to the innovation and development of the healthcare landscape. The firm's team comprises professionals with extensive experience in investment, entrepreneurship, operations, management, life sciences research, and clinical practice, providing valuable support to its portfolio companies. HM Venture Partners is headquartered in San Francisco, California, with additional offices in Rochester, Minnesota, and Beijing, China. The firm's contact email is info@hmventurepartners.com, and its website is https://hmventurepartners.com.